141
|
|
|
Glucagon |
GLP-1, GLP1, GLP2, GRPP |
Alzheimer disease, Anorexia, Bradycardia, Catalepsy, Colitis, Colonic neoplasms, Congestive heart failure, Constipation, Diabetes mellitus type 2, Heart disease, Heart failure, Hyperglycemia, Hyperinsulinism, Hyperkinesia, Hyperlipidemia, Hyperlipoproteinemia, Hypertension, Hypotension, Multiple sclerosis, Obesity, Prediabetes, Psoriasis, Stomach disease, Vascular diseaseView all (9 more) |
142
|
|
|
Glucagon receptor |
GGR, GL-R, MVAH |
|
143
|
|
|
GTP cyclohydrolase 1 |
DYT14, DYT5, DYT5a, GCH, GTP-CH-1, GTPCH1, HPABH4B |
Alzheimer disease, Sickle cell anemia, Dopa-responsive dystonia, Bipolar disorder, Ischemic stroke, Color vision deficiency, Bipolar depression, Diabetes mellitus type 2, Diabetic angiopathies, Diabetic peripheral angiopathy, Dry eye syndrome, Dyskinesia, drug-induced, Dystonia, Dystonia musculorum deformans, Dystonia, dopa-responsive, with or without hyperphenylalaninemia, Genetic torsion dystonia, Hypertension, Intellectual developmental disorder, Myocardial ischemia, Non-organic psychosis, Obesity, Osteoarthritis, Parkinson disease, Psychotic disorders, Rheumatoid arthritis, SchizophreniaView all (11 more) |
144
|
|
|
GTP cyclohydrolase I feedback regulator |
GFRP, HsT16933, P35 |
|
145
|
|
|
Glucokinase |
FGQTL3, GK, GLK, HHF3, HK4, HKIV, HXKP, LGLK, MODY2, PNDM1 |
Bone marrow failure syndromes, Carbohydrate metabolism disease, Ischemic heart disease, Congenital glucokinase-related hyperinsulinism, Congenital hyperinsulinism, Coronary artery disease, Diabetes mellitus, Diabetes mellitus type 2, Experimental diabetes, Diabetes mellitus permanent neonatal, Gestational diabetes, Gout, Hyperglycemia, Hyperinsulinemic hypoglycemia, Hyperinsulinism, Hypertension, Hypoglycemia, Intestinal disaccharide malabsorption, Neonatal diabetes mellitus, Liver cirrhosis, Maturity-onset diabetes of the young (mody), Metabolic syndrome, Maturity-onset diabetes of the young, Myocardial ischemia, Osteoarthritis, PrediabetesView all (11 more) |
146
|
|
|
Glucokinase regulator |
FGQTL5, GKRP |
Ankylosing spondylitis, Atrial fibrillation, Bipolar disorder, Cancer, Cardiovascular disease, Cholecystolithiasis, Kidney disease, Coronary artery disease, Crohn disease, Diabetes mellitus, Diabetes mellitus type 2, Diabetic eye disease, Diabetic retinopathy, Hyperlipidemia, Lipoprotein lipase deficiency, Gallstones, Gestational diabetes, Gout, Heart failure, Hypertriglyceridemia, Hyperuricemia, Hypogonadism, Inflammatory bowel disease, Intrahepatic cholestasis of pregnancy, Kidney failure, Liver disease, Macular telangiectasia, Metabolic syndrome, Nephrolithiasis, Neuropathy, Nonalcoholic fatty liver disease, Peripheral neuropathy, Psoriasis, Schizophrenia, Sclerosing cholangitis, Stroke, Testicular disease, Ulcerative colitis, Urolithiasis, Uterine fibroid, Venous thromboembolismView all (26 more) |
147
|
|
|
Glutamate-cysteine ligase catalytic subunit |
CNSHA7, GCL, GCS, GLCL, GLCLC |
Amino acid metabolism disorder, Congenital nonspherocytic hemolytic anemia, Hemolytic anemia, Benign prostatic hyperplasia, Non-small-cell lung carcinoma, Contact dermatitis, Coronary vessel anomalies, Cystic fibrosis, Diabetes mellitus type 2, Hereditary hemolytic anemia, Hypertension, Lung cancer, Lung neoplasms, Microphthalmos, Myocardial infarction, Myocardial ischemia, Ovarian serous carcinoma, SchizophreniaView all (3 more) |
148
|
|
|
Glutamate-cysteine ligase modifier subunit |
GLCLR |
|
149
|
|
|
Glial cells missing transcription factor 2 |
FIH2, GCMB, HRPT4, hGCMb |
|
150
|
|
|
GCN1 activator of EIF2AK4 |
GCN1L, GCN1L1, PRIC295 |
|
